A Randomised, Double-blind, Placebo-controlled, Dose-finding Study Evaluating Efficacy, Safety, and Tolerability of Different Oral Doses of BI 1819479 Over at Least 24 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 30 Jun 2025
At a glance
- Drugs BI 1819479 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 24 Jun 2025 Planned End Date changed from 3 Feb 2026 to 9 Jan 2026.
- 24 Jun 2025 Planned primary completion date changed from 3 Dec 2025 to 14 Nov 2025.
- 16 May 2025 Status changed from recruiting to active, no longer recruiting.